Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most ...
Tag: Eli Lilly and Co
Alphabet’s new CFO was in the middle of the GLP-1 boom. Now she’s onto generative AI
Alphabet incoming CFO Anat Ashkenazi, who spent 23 years at Eli LillyEli LillyAlphabet's outgoing finance chief, Ruth Porat, spent the ...
Alphabet taps Eli Lilly’s Anat Ashkenazi as new CFO
A view of Google Headquarters in Mountain View, California, United States on April 16, 2024. Tayfun Coskun | Anadolu | Getty ...
This new weight loss drug ETF bets big on two of the industry’s leading players
A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs.Roundhill Investments' GLP-1 & Weight ...
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Brendan ...
How digital health companies are capitalizing on the GLP-1 boom
Patent protection for Wegovy — Novo Nordisk's blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and ...
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Mike Blake ...
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023.Jeenah Moon | The ...
Diabetes drug similar to Ozempic helped slow progression of Parkinson’s disease in small trial
The coronal view of a human brain of a patient suffering from Parkinson's diseaseSherbrooke Connectivity Imaging Lab | Getty ImagesA ...
Two fresh ways to play the weight loss and megacap tech hype
A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks.In health ...
